Literature DB >> 12759887

Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis.

S T W Mann1, H Stracke, U Lange, H U Klör, J Teichmann.   

Abstract

The aim of this study was to examine bone mineral density (BMD) and bone metabolism in patients with chronic pancreatitis to determine if increased severity of the disease would correlate with increased bone loss. Between October 1999 and September 2000, we investigated 42 patients with an average age of approximately 53 years suffering from chronic pancreatitis, as well as 20 healthy male controls with an average age of 49 years. Dual energy x-ray absorptiometry (DEXA) was performed on patients and controls, and serum levels of parathyroid hormone (PTH), osteocalcin (OC), carboxy-terminal propeptide of type I procollagen (CICP), bone-specific alkaline phosphatase (BAP), 1,25(OH)(2) vitamin D(3) and 25(OH) vitamin D(3), as well as fecal elastase 1 were also determined. The severity of chronic pancreatitis in patients was determined via endoscopic retrograde cholangiopancreatography (ERCP) and assigned to 1 of 3 grades based on the Cambridge classification. BMD of patients with chronic pancreatitis was markedly decreased compared to controls (means in patients: DEXA lumbar vertebra anterior/posterior (LV ap) 96.8% +/- 4.2%, DEXA Ward's triangle (WARD) 92.2% +/- 5.2%; controls: DEXA LV ap 98.7% +/- 3.7%, DEXA WARD 97.1% +/- 3.1%; P <.05 and P <.0001) and correlated with the various Cambridge-grades (DEXA LV ap and DEXA WARD, P <.01). Fecal elastase 1 showed sensitivities of 14%, 87%, and 95% for the Cambridge-grades I, II, and III, respectively, and correlated with this classification of severity of chronic pancreatitis (P <.01). Furthermore, fecal elastase 1 of patients correlated the same way with both D(3)-vitamins (P <.01), as well as with parameters of BMD (P <.01). If fecal elastase 1 in patients was below 200 micro g/g, then the BMD and vitamin D(3) values were also significantly decreased compared to those with fecal elastase 1 above 200 micro g/g. In patients with Cambridge grades II and III 1,25(OH)(2)D(3) was markedly decreased (26.7 +/- 7.7 pg/mL and 27.6 +/- 9.0 pg/mL) compared to those with Cambridge grade I (38.0 +/- 10.5 pg/mL; between I and II, P =.027; between I and III, P =.033). 25(OH)D(3) was not significantly different within the various Cambridge groups (P =.07). Compared to controls, both D(3) vitamins, as well as fecal elastase 1, were extremely low (means in patients: fecal elastase 1, 140.7 +/- 75.7 micro g/g; 1,25(OH)(2)D(3), 29.9 +/- 9.5 pg/mL; 25(OH)D(3), 26.7 +/- 9.7 nmol/L; controls: fecal elastase 1, 694.9 +/- 138.6 micro g/g; 1,25(OH)(2)D(3), 67.5 +/- 4.3 pg/mL; 25(OH)D(3), 69.5 +/- 13.5 nmol/L). A significant correlation was observed between increased severity of chronic pancreatitis based on both endoscopic retrograde cholangiopancreatography and levels of fecal elastase 1, with decreased circulating levels of vitmain D(3) and decreased BMD. This supports a connection between the inflammatory destruction of the pancreas (Cambridge classification), exocrine pancreatic insufficiency (fecal elastase 1), altered levels of vitamin D metabolites, and loss of skeletal mass. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759887     DOI: 10.1053/meta.2003.50112

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  21 in total

1.  The effect of primary hyperparathyroidism on pancreatic exocrine function.

Authors:  P Sisman; M Avci; A Akkurt; A B Sahin; O O Gul; C Ersoy; E Erturk
Journal:  J Endocrinol Invest       Date:  2017-08-02       Impact factor: 4.256

2.  Prevalence and Risk Factors for Osteopathy in Chronic Pancreatitis.

Authors:  Xin-Ying Tang; Nan Ru; Qing Li; Yang-Yang Qian; Hui Sun; Jia-Hui Zhu; Lin He; Yuan-Chen Wang; Liang-Hao Hu; Zhao-Shen Li; Wen-Bin Zou; Zhuan Liao
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

Review 3.  Childhood obesity, bone development, and cardiometabolic risk factors.

Authors:  Norman K Pollock
Journal:  Mol Cell Endocrinol       Date:  2015-03-27       Impact factor: 4.102

Review 4.  Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis.

Authors:  Sikarin Upala; Veeravich Jaruvongvanich; Karn Wijarnpreecha; Anawin Sanguankeo
Journal:  J Bone Miner Metab       Date:  2016-12-07       Impact factor: 2.626

5.  An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study.

Authors:  Sinead N Duggan; Christina Purcell; Mark Kilbane; Myra O'Keane; Malachi McKenna; Peter Gaffney; Paul F Ridgway; Gerard Boran; Kevin C Conlon
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

6.  Nutritional Considerations in Pediatric Pancreatitis: A Position Paper from the NASPGHAN Pancreas Committee and ESPGHAN Cystic Fibrosis/Pancreas Working Group.

Authors:  Maisam Abu-El-Haija; Aliye Uc; Steven L Werlin; Alvin Jay Freeman; Miglena Georgieva; Danijela Jojkić-Pavkov; Daina Kalnins; Brigitte Kochavi; Bart G P Koot; Stephanie Van Biervliet; Jaroslaw Walkowiak; Michael Wilschanski; Veronique D Morinville
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-07       Impact factor: 2.839

7.  The management of acute and chronic pancreatitis.

Authors:  Peter A Banks; Darwin L Conwell; Phillip P Toskes
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-02

8.  Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation.

Authors:  C-L Shen; J K Yeh; C Samathanam; J J Cao; B J Stoecker; R Y Dagda; M-C Chyu; D M Dunn; J-S Wang
Journal:  Osteoporos Int       Date:  2010-03-20       Impact factor: 4.507

9.  Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats.

Authors:  C-L Shen; J K Yeh; J J Cao; O L Tatum; R Y Dagda; J-S Wang
Journal:  Osteoporos Int       Date:  2010-01-13       Impact factor: 4.507

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.